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Abstract
Allometric principles were used to discern cross-species differences in (±)-tramadol disposition and formation of its primary analgesic metabolite,
(±)-O-desmethyl-tramadol (M1). Species differences in formation of M1 may help predict the analgesic effectiveness of tramadol. Tramadol was administered
intravenously by a zero-order (constant infusion) process or rapid bolus dose and racemic concentrations of tramadol and M1 measured. Data were pooled
to define differences between species (human, rat, cat, dog, goat, donkey and horse). A two-compartment linear disposition model with first-order elimination
was used to describe tramadol and M1 disposition. Slow metabolizers were detected in 6% of the population and tramadol clearance to M1 was 16.2% that
of extensive metabolizers. Tramadol clearance to M1 was slower and tramadol clearance by other pathways was faster in rats, dogs, and horses compared to
humans. There are substantial differences between species in the pharmacokinetics of tramadol and its M1 metabolite, which are not explained by differences
in body weight. The hypothesis that volumes of distribution are similar across species was shown not to be true. M1 exposure in the goat, donkey and cat was
comparable to humans, which indicates it is likely to be an effective analgesic at typically used doses in these species but not in dogs or horses.

ABBREVIATIONS
Tramadol: (±)-Tramadol; M1: (±)-O-Desmethyl-Tramadol;
CLPM: Clearance to M1; CLPO: Tramadol Clearance by Other
Routes; QP: Inter-Compartmental Clearance; CLMO: Clearance

of M1; VP1: Central Volume; VP2: Peripheral Volume; QM:
M1 Inter-Compartmental Clearance; VM1: Central Volume;
VM2: Peripheral Volume; T½: Elimination Half-Life; M5: O-NDidesmethyl-Tramadol; M2: N-Desmethyl-Tramadol; Fm:
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Fraction of Tramadol Converted to M; Fo: Fraction of Tramadol
Eliminated by Other Pathways; HPLC: High Performance
Liquid Chromatography; GCMS: Gas Chromatography Mass
Spectrometry; LC/MS/MS: HPLC-Coupled Tandem Mass
Spectrometry; PPV: Population Parameter Variability; RSE:
Relative Standard Error; RUV: Residual Unidentified Variability

INTRODUCTION

Pharmacokinetic models describing concentrations, e.g. in
plasma, of parent and metabolite after administration of the
parent compound must make assumptions because the system
is a priori unidentifiable. Tramadol is a centrally acting racemic
analgesic structurally related to morphine that mediates analgesia
by multiple mechanisms [1]. The moiety (+)-tramadol and its
metabolite (+)-O-desmethyl-tramadol (M1) are weak µ-opioid
receptor agonists relative to morphine and the antinociceptive
effects of tramadol are attributed to a combination of
mechanisms. Along with µ-opioid receptor activity, (+)-tramadol
and (+)-M1 stimulate neuronal serotonin efflux while reuptake
is inhibited by (+)-tramadol [2,3]. Further analgesia is caused by
(-)-tramadol competitively inhibiting noradrenaline reuptake in
the spinal cord [4].
Ninety percent of 14C label can be recovered in the urine
after oral administration of 14C tramadol to humans [5]. Twelve
percent of tramadol and 15% of M1 (expressed as fraction
of the tramadol dose) are excreted in the urine unchanged in
humans [6]. The mean elimination half-life (T½) is 6 hours and
the total clearance following intravenous administration has
been reported to be 29 L/h in adult humans [7,8]. In all species,
the main tramadol metabolites are M1 and M1 glucuronide and
sulfate conjugates, O,N-didesmethyl-tramadol (M5) and M5
conjugates, and N-desmethyl-tramadol (M2). In rats and dogs,
only 1% of administered tramadol is excreted unchanged in the
urine [5].
O-Demethylation of tramadol to M1, the main analgesic
metabolite, is catalyzed by CYP2D6. CYP2D6 polymorphisms
have been shown to influence M1 production and its subsequent
analgesic effect in humans [9]. (+)-M1 alone has been shown to
provide substantial antinociception in rats [10].

The pharmacokinetics of tramadol and M1 after intravenous
administration of tramadol have been reported in several adult
human studies [8,9,11-13] as well as in dogs [14-16], goats [17],
horses [18-21], donkeys [22], cats [23] and rats [24]. Of particular
importance to the current analysis, one of these studies observed
M1 concentrations after direct intravenous administration of
M1, allowing estimation of the volume of distribution of M1 [14].
Data have been pooled from these studies in order to construct
a pharmacokinetic model for tramadol and M1. This model has
been used to define quantitatively the elimination pathway of
tramadol and M1 by comparison to adult humans. The use of
allometric principles allows comparison of species differences by
normalizing size, which ranges over three orders of magnitude.
The assumption that volumes of distribution (such as for M1)
are similar across species has been tested using direct estimates
from studies in dogs.

MATERIALS AND METHODS

Tramadol was administered intravenously in all studies.
J Pharmacol Clin Toxicol 2(1): 1023 (2014)

All non-human species were fasted for 8 to 12 hours prior to
administration of tramadol except cats, which had free access
to food during the study (Table 1). Human data were acquired
from 57 healthy and 56 post-surgery adults. All non-human
species were considered to be in the adult stage of their lifespan.
Institutional informed consent and ethical approval was obtained
for all studies. Specific details can be found in the original
publications. All references to tramadol and its M1 metabolite are
to the (±) racemic form.

Population parameter estimations

A two-compartment (central and peripheral) linear
disposition model with zero-order input and first-order
elimination fitted the tramadol concentrations from all species
combined together more closely than a single compartment
model. M1 disposition was also better described by a twocompartment model, with first-order input from the tramadol
central compartment and first-order elimination (Figure 1). The
model parameters were clearance of tramadol (parent) to M1
(CLPM), tramadol clearance by other routes (CLPO), tramadol
inter-compartmental clearance (QP), tramadol central volume
(VP1), tramadol peripheral volume (VP2), clearance of M1
(CLMO), inter-compartmental clearance of M1 (QM) and M1
central volume (VM1) and peripheral volume (VM2).
When M1 is not administered directly, the fraction of tramadol
converted to M1 (Fm), and the fraction of tramadol eliminated
by other pathways (Fo) are unknown. Two different models with
distinct assumptions were used to try to distinguish CLPO from
CLPM and to identify CLMO and VM:

1. Complete conversion in all species (Fm = 1): Assumes
all tramadol is converted to M1. Estimates of CLMO / Fm
and VM1 / Fm are species specific. CLPO is assumed to
be zero. While it is obvious that this assumption cannot
be true (because unchanged tramadol is known to be
excreted and other metabolites have been identified), it
does permit local identifiability of some key parameters
and provides a good description of the time course of
concentration.

2. Metabolite volume is the same as in the dog (VM1 = VM1dog):
VM1 was estimated in 3 dogs after administration of M1.
If the estimate of VM1 / Fm is greater than VM1 estimated
in dogs then it may be assumed that VM1 is the same as
the dog. If VM1 / Fm is less than VM1 for dogs, then VM1
must be less than the value in dogs but otherwise cannot be
identified. The VM1 = VM1dog assumption allows Fm to be
identified and CLPO can be distinguished from CLPM [25].

Parameter estimates were obtained using a nonlinear mixed
effects approach, which can account for population parameter
variability (between and within subjects), residual variability
(random effects), and parameter differences predicted by
covariates (fixed effects). Parameter estimation was performed
using NONMEM version VII level 1.1 with the first-order
conditional interaction method. Standard errors of the estimates
were obtained by non-parametric bootstrapping [26]. Models
were compiled with Intel Visual Fortran version 10.1.029 and
executed on an Intel Xeon E5335 Processor with Microsoft
Windows 2003 Server Service Pack 2. Model building was based

2/12

Holford et al. (2014)
Email:

Central
Table 1: Summary of studies used and analytical methods.
Publication

[8,11,12]

[13]

[9]

[14]

[14]

[15]

[17]

[20]

[21]

[23]

[24]

[22]

Study code

3

5

7

20

21

22

30

40

41

50

60

70

41

16

56

Species

Number subjects

Human Human Human

100 mg
Dose (mg/kg) of
bolus
tramadol HCL ex100 mg 3 over
then, 50
cept M1 (base) for
bolus 18 min
mg over
study 21
30 min
Duration of sam24-30.5
48
3
pling (h)
Average observations/subject (tra15
13
3
madol)
Average observations/subject
0
13
3
(M1)
Analytical method

GCMS

LC/MS

Enantiomer

Dog

Dog

Goat

Horse

Horse

Cat

Rat

Donkey

4.4

1 (M1)

4

2

2

5

2

20

2.5 over 3
min

6

4

24

15

24

8
9

8

12

5

24

8

8

6

7

14

7

12

8

6

6

8

HPLC Fluorescence
detection
[36,37]
Racemate

No details
of assay
performance

LLOQ (tramadol
and M1)
CV%
Mean weight kg
(range)

Dog

71.1 (5898)

9.4
(7.3-12.4)

3

-

6

5

9

7

6

16

6

6

4

8

HPLC Fluo- HPLC UlHPLC FluoHPLC Fluorescence traviolet LC/MS/ rescence LC/MS/ rescence
detection detection
MS
detection MS [23] detection
[21]
[17]
[21]
[38]
Race+/- enantiRacemate
Racemate Racemate Racemate
mate
omer
0.005
mg/L

<4% in7% interter- and
and intraintraday
day

20 (18-23)

0.025,
0.010
mg/L

47.8
(40.754.4)

0.001
mg/L

0.005
mg/L

12

9

HPLC Fluorescence
detection
[22]
Racemate

0.001
mg/L

0.0025mg/L

0.005
mg/L

7% intra
day

<15%

7% interday

402.7
513.5
4.1 (3.8(350-492) (479-545)
4.4)

0.251
(0.2300.295)

343.5
(300-380)

Abbreviations: M1: (±)-O-desmethyl-tramadol; HCL: hydrochloride; LLOQ: lower limit of quantitation; CV: coefficient of variation; HPLC: high
performance liquid chromatography; GCMS: gas chromatography mass spectrometry; LC/MS/MS: HPLC-coupled tandem mass spectrometry

on NONMEM’s objective function and by a visual predictive check
[27] with prediction correction [28]. Models were nested and
an improvement in the objective function was referred to the
chi-squared distribution to assess statistical significance, e.g. an
objective function change of 3.84 is significant with Type I error
of 0.05 with one additional parameter in the model.
Reported tramadol hydrochloride doses were converted to
base tramadol, where 1 mg tramadol hydrochloride is equal to
0.8784 mg of tramadol.

M1 concentrations were converted to tramadol milligram
equivalents for a simultaneous parent and metabolite fit using
a molecular weight of 249.38 mg mmol-1 for M1 and 263.38 mg
mmol-1 for tramadol (molar ratio 0.947). M1 measurements
from dog study 20 were excluded from analysis because of
contamination with other tramadol metabolites. All other assays
are believed to have been selective for M1. Stereoselective
concentration measurements were converted to racemic
concentrations by summation of stereoisomer concentrations.

Covariate analysis

Fractional differences relative to adult humans were
estimated for each population parameter.
J Pharmacol Clin Toxicol 2(1): 1023 (2014)

Clearance and volume parameters for tramadol and M1 in
all species were standardized to a body weight of 70 kg using an
allometric model [29] (Equation 1)
 Wi 
Fsize = 

 WSTD 

PWR

				

(1)

where Wi is the weight in the ith individual. Allometric scaling
with a PWR exponent of ¾ for clearance and 1 for volume of
distribution was employed due to its strong theoretical and
empirical basis [30]. Fsize is the allometrically scaled fraction of
the standard weight, WSTD.

A mixture model was used to distinguish slow from extensive
metabolizers of tramadol on the basis of their phenotype. This
method estimates the fraction of all subjects (human and nonhuman) who appear to be in a slow metabolizer subgroup and
the value of CLPM relative to CLPM in extensive metabolizers.
Group parameters were based on fixed effects for clearance
using species and size. Equation 2 illustrates how a group value
of CLPMGRP is calculated from a standard value of CLPMSTD (adult
human 70 kg).
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indeed be smaller than the dog, but in other species the finding of
a larger VM1 / Fm could be explained by an additional pathway
for tramadol elimination (CLPO) other than formation of M1. In
cats either the true VM1 is less than that of dogs, or CLPO is zero.

Figure 1 Schematic representation of the pharmacokinetic
model for tramadol and its M1 metabolite. A two-compartment
linear disposition model describes the parent drug with intercompartmental clearance (QP). Total clearance of tramadol is the sum
of CLPM (clearance to M1) and CLPO (clearance by other routes). An
additional two compartments for the metabolite M1 are linked to the
tramadol central compartment by M1 formation (CLPM). QM is the
inter-compartmental clearance of M1. CLMO is the clearance of M1.

CLPMGRP = CLPM STD Fspecies Fsize

(2)
		
Individual parameter estimates (e.g.. CLPMi) were predicted
from the group estimate and the variance of ηi, the random
between subject differences in the parameter, using an
exponential model (Equation 3):
CLPMi = CLPMGRP exp(ηi )

			



(3)

Residual unidentified variability was described using a
combined proportional and additive residual error model
for each observation prediction with random differences,
εPROP, εADD. Between-subject differences in residual error were
separately identified for tramadol and M1. The variance of the
residual unidentified variability, ηRUV,i, was estimated [31]. This
is illustrated for a concentration observation prediction, C, in
Equation 4.
Y = C (1 + ε PROP ) + ε ADD )exp(ηRUV ,i )

RESULTS AND DISCUSSION

		

(4)

The first assumption that was tested (Fm = 1) assumed
complete conversion of tramadol to M1. All estimates of VM1 /
Fm were larger than the VM1 estimated in dogs except in cats
(74%) and donkeys (72% of dog VM1). The estimate of VM1 /
Fm is always an upper bound on the value for VM1 because Fm
must be <=1. This means that the VM1 in cats and donkeys must
J Pharmacol Clin Toxicol 2(1): 1023 (2014)

A second assumption (VM1 = VM1dog) was then tested by
assuming VM1 in all species was equal to the dog (except the
cat and donkey), which allowed estimation of CLPO. The Fm =
1 assumption was kept for the cat and donkey and VM1 / Fm
was estimated separately with CLPO fixed to zero. The VM1 =
VM1dog objective function (17343.5) was similar to the Fm = 1
model (17350.8), which confirms the inter-changeability of the
Fm = 1 with VM1 = VM1dog assumptions. A major improvement
in the objective function (17305.7) was obtained by allowing
total tramadol clearance in dog Studies 20 and 21 to be different
(4.74 times bigger; 14% bootstrap relative standard error
(RSE)) compared to dog Study 22. Removing the mixture model
to distinguish two distributions of CLPM from the final model
worsened the objective function from 17305.7 to 17319.8. This is
a significant (p=0.00085) change for the removal of 2 parameters
and provides strong support for the existence of a subgroup of
slow metabolizers relative to the rest of the population. The
parameter estimates for this model including 2 distributions for
clearance and different total tramadol clearance for 2 of the dog
studies are shown in Tables 2 to 4.

The visual predictive check plots for tramadol (Figure 2) and
M1 (Figure 3) show good agreement between the predicted and
observed median and 90% intervals. Parameter estimates for the
VM1 = VM1dog model are shown in Tables 2, 3 and 4. The mixture
Table 2: Human parameter estimates and population parameter
variability across all species.
Value
(RSE)

Parameter Description

Units

PPV

L/h/70
kg
L/h/70
1.70 (27%)
kg
L/h/70
18.4 (9%)
kg
L/h/70
105 (29%)
kg

CLPMextensive Clearance of tramadol to M1 10.5 (13%)

CLPMslow
CLPO
QP

VP1
VP2

CLMO
QM

VM1

VM2

CLPM in slow metabolizers
Clearance of tramadol by
other pathways
Inter-compartmental
clearance of tramadol

Central volume of tramadol
Peripheral volume of
tramadol
Clearance of M1

Inter-compartmental
clearance of M1

Central volume of M1a

Peripheral volume of M1

0.525
0.059
0.762
0.647

90 (16%) L/70 kg 0.549

79 (17%) L/70 kg 0.633

84.2 (10%)
274
(112%)
78.9

L/h/70
0.154
kg
L/h/70
1.65
kg

L/70 kg 0.401

131 (24%) L/70 kg 0.412

Model assumed VM1 was the same as in dogs.

Fixed to value estimated in dogs administered M1 intravenously.

a

Abbreviations: PPV: Population Parameter Variability ( sqrt ( NONMEM
OMEGA estimate ) ); RSE: Relative standard error (bootstrap standard
error / estimate x 100); M1: (±)-O-desmethyl-tramadol; CLPM:
clearance to M1; CLPO: tramadol clearance by other routes; QP: intercompartmental clearance; CLMO: clearance of M1; VP1: central volume;
VP2: peripheral volume; QM: M1 inter-compartmental clearance; VM1:
central volume; VM2: peripheral volume
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Table 3: Correlation of population parameter variability.

CLPMextensive
1

CLPMextensive

CLPO

-0.021

VP1

-0.477

VP2

CLMO

QP

0.754
0.888

CLMO

1

VM1

0.886

CLPO

VP1

1

0.863

0.264

QP

1

-0.04

-0.094
VM1

-0.485

1

VM2

QM

VP2

1

0.854

1

QM

VM2

1

-0.609

1

Model assumed VM1 was the same as in dogs.
Abbreviations: CLPM: clearance to M1; CLPO: tramadol clearance by other routes; QP: inter-compartmental clearance;
CLMO: clearance of M1; VP1: central volume; VP2: peripheral volume; QM: M1 inter-compartmental clearance; VM1:
central volume; VM2: peripheral volume
Table 4: Residual unidentified variability (RUV) and population parameter variability.
Parameter
CVCP
SDCP
CVCM
SDCM

Description
Proportional error tramadol
Additive error tramadol
Proportional error M1
Additive error M1

Value
0.123
0.901
0.223
0.580

Units
mcg/L
mcg/L

PPV
0.391

0.370

Model assumed VM1 was the same as in dogs. CVCP and CVCM are fractional coefficients of variation. Correlation of PPV RUV tramadol with PPV RUV
M1 = -0.221.
Abbreviations: PPV: Population Parameter Variability; M1: (±)-O-desmethyl-tramadol

Human

Dog

Goat
J Pharmacol Clin Toxicol 2(1): 1023 (2014)
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Goat

Horse

Cat

Rat

Donkey
J Pharmacol Clin Toxicol 2(1): 1023 (2014)
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Figure 2 Visual predictive check for tramadol. Vm1 = VM1dog model. All plots show median and 90% intervals (solid and dashed lines). Left hand
plot shows all observed concentrations. Right hand plot shows prediction corrected percentiles (10, 50, 90) for observations (lines with symbols)
and predictions (lines) with 95% confidence intervals for prediction percentiles (gray shaded areas).

model for identification of M1 metabolizer type estimated that
6.0% (49% bootstrap RSE) of the overall population (human and
non-human) were slow metabolizers and that these individuals
have 16.2% (24% bootstrap RSE) of the CLPM of extensive

metabolizers. All slow metabolizers were human except for 1
horse in study 41.
A fundamental assumption of the modelling of inter-species
differences was the appropriateness of the theoretical allometric

Human

Dog

Goat
J Pharmacol Clin Toxicol 2(1): 1023 (2014)
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Goat

Horse

Cat

Rat

Donkey
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Figure 3 Visual predictive check for the M1 metabolite of tramadol. Vm1=VM1dog model. All plots show median and 90% intervals (solid and dashed
lines). Left hand plot shows all observed concentrations. Right hand plot shows prediction corrected percentiles (10, 50, 90) for observations (lines
with symbols) and predictions (lines) with 95% confidence intervals for prediction percentiles (gray shaded areas). All horse M1 concentrations
after 8 hours are from the same subject ID = 40002 [20].

coefficients of ¾ for clearance and 1 for volume parameters.
Although a very wide range of weights were included when
considering all species, the use of species-specific parameters
means that weight differences are only reflected within each
species. The within-species range of weights was relatively small
and thus testing if the allometric exponents were different from
theoretical values could not be performed with any confidence
[29].
After using allometry to account for differences in size, there
remain large between-species differences in tramadol and M1
pharmacokinetic parameters. These must be attributed to other
factors such as genotype, diet and environment, which are not
related to size. Although protein binding changes with pH and
carnivorous species tend to have a blood pH lower than that
of herbivorous species, tramadol is only 20% protein bound in
humans [7] and 15% in dogs [32] so plasma protein binding is

Table 5: Comparison of pharmacokinetic parameters across species.
Parameter

Rat

CLPMextensive

0.658 (35%) 3.5 (19%)

CLPO
QP

VP1

VP2

Cat

2.79 (27%)

0

2.12 (35%)

1.03 (24%)

0.193 (66%) 0.62 (19%)

1.37 (35%)

1.12 (12%)

Goat

0.517

0.109 (37%)

7.39a

0.306 (55%)

2.02 (26%)

0.696 (153%)

VM1

1

0.104 (38%) 0.157 (29%) 2.27

b

1

0.742 (27%) 1b
0.742

The total clearance of tramadol and its elimination by
conversion to M1 show marked differences between species
(Table 5, Figure 4, Figure 5). The dog is outstanding in having
much lower clearance to M1 in Study 22 (CLPM). We have shown
that the assumption that the volume of distribution of M1 is

Dog study 22

a

0.394 (45%) 0.389 (29%) 1.13b

VM2

By assuming the volume of distribution of M1 in the dog is
the same as that in other species (except the cat and donkey) it
was possible to identify and quantify the clearance of tramadol
by other pathways. The mixture model estimate of 6.0% slow
metabolizers based on the distribution of CLPM agrees with the
fraction of slow CYP2D6 genotypes reported in the literature for
humans [33]. Our estimate of the relative clearance of tramadol
to its M1 metabolite of 16.2% in slow metabolizers is the only
estimate we are aware of because of the impracticality of directly
determining this fraction in humans.

Dog study 20, 21

CLMO
QM

not expected to explain the large differences observed.

1

1.56 (24%)

0.156 (224%)

0.771 (79%)

Donkey

Horse study 40

Horse study 41

1.13 (33%) 1.71 (31%)

0.39 (33%)

0.718 (31%)

2.94 (70%) 1.73 (61%)

1.33 (34%)

4.72 (25%) 0

7.89 (12%)

0.243 (59%) 0.0405 (111%) 0.669 (25%)

5.99 (13%)

0.605 (35%)

0.983 (27%)

0.146 (83%)

0.579 (28%) 0.344 (26%)

0.937 (15%)

0.397 (20%)

0.287 (86%)

2.23 (189%) 12.1 (31%)

2.04 (67%)

0.216 (31%)

0.827 (40%)
1

1

0.448 (86%) 1.86 (35%)
1

1

0.719 (31%)
0.719

3.95 (31%)
1
1

0.691 (41%)
1

1

Values are fractional differences relative to human. Relative standard error (bootstrap standard error/estimate x 100) is shown in parentheses. VM1
and VM2 were assumed to be the same in all species except the donkey which had an estimate of VM1 / Fm and VM2 / Fm that was 0.719 × and the cat
0.742 × the value of VM1 in the dog (Study 21).

CLPMextensive and CLPO for dog study 20, 21 calculated from dog study 22 times 4.74 (ratio of total parent metabolite clearance in dog study 20, 21 to
dog study 22).
a

Estimated from dog study 21 only

b

Abbreviations: CLPM: clearance to M1; CLPO: tramadol clearance by other routes; QP: inter-compartmental clearance; CLMO: clearance of M1; VP1:
central volume; VP2: peripheral volume; QM: M1 inter-compartmental clearance; VM1: central volume; VM2: peripheral volume
J Pharmacol Clin Toxicol 2(1): 1023 (2014)
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Figure 4 Weight-predicted (VM1 = VM1dog model) tramadol total clearance (CLPM + CLPO) compared to human allometric prediction (solid line).
Numbers for each symbol refer to studies listed in Table 1.
1000
CLPM
Human 3,5,7

100

Rat

Clearance L/h

Cat
Dog 21
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1
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1

10

100

1000
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Figure 5 Individual predicted (VM1 = VM1dog model) tramadol clearance to M1 (CLPM) compared to human allometric prediction (solid line).
Numbers for each symbol refer to studies listed in Table 1.

similar in all species cannot be true for the cat and the donkey.
There are also large within-species differences in volumes of
distribution of tramadol that raise further doubts about the
assumption that the volume of distribution of M1 is the same in
all species.

Two major limitations are recognized in this attempt to
describe the pharmacokinetics of tramadol and M1. The first is
the necessary assumption that the volume of distribution of M1
is the same in dogs and other species (except the cat and donkey).
Unless M1 is administered directly, it is not possible to determine
the volume of distribution of M1, though an estimate may be
obtained under special conditions [34]. Without knowing (or
assuming) this volume, it is impossible to determine the fraction
of tramadol that is converted to M1 by a first-order process by
J Pharmacol Clin Toxicol 2(1): 1023 (2014)

only measuring M1 concentrations. The second limitation is
the use of racemic concentrations of tramadol and M1, which
obscures the different pharmacokinetics of the stereoisomers.
This remains a challenge for future studies in those species
where only the racemate has been studied.
It is difficult to determine if tramadol has pain-relieving
activity in non-human species. Human subjects with the CYP2D6
genotype associated with reduced formation of M1, have worse
analgesia [9]. Furthermore, the M1 metabolite is 6 times more
potent than tramadol in non-human models of analgesia [35]. If
M1 is the main determinant of pain relief, then typical dose rates
can be used with species-specific values for CLPM, CLPO and
CLMO to predict the M1 average concentration. Comparison of
the M1 concentration with those known to be effective in humans
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Table 6: Prediction of M1 average steady state concentration relative to human at typical dose rates of tramadol hydrochloride.
Species

Reference for Analgesic Dose

Human

[39]*

2

6

Cat

[41]

4

6

Rat

Dog

Goat

Donkey

Horse study 40

Horse study 41

[40]

[42]

None

None

[43]**

Dose (mg/kg) Dose Interval (h) Weight (kg)
5

10
2

2

2

2

Tramadol average concentration = Dose Rate / ( CLPM + CLPO )

Rate of conversion to M1 = Tramadol average concentration × CLPM

Relative to Human M1 (84 mcg/L)

70

100%

4

692%

6

0.5

6

15

43.4%

350

221%

500

10%

6

6

6

6

50

450

60%

68%

0.8%

M1 average concentration = (Rate of conversion to M1) / CLMO

CLPO and CLMO in cats and donkeys are CLPO / Fm and CLMO / Fm.

*=1 mg/kg/6h produced minimum effective M1 analgesic concentrations in patients with post-operative pain around 50% of those predicted from 2
mg/kg/6h (84 mcg/L)
**=2mg/kg intravenous single dose to horses did not produce analgesia

can be used to see if dosing rates used in non-human species are
likely to be effective. Table 6 shows the predicted M1 average
steady state concentrations relative to humans. It seems unlikely
that effective pain relief would be achieved in dogs or horses with
typically used doses.

CONCLUSION

There are substantial differences between species in the
pharmacokinetics of tramadol and its primary metabolite, which
are not explained by differences in body weight. The hypothesis
that volumes of distribution are similar across species was
shown not to be true. M1 exposure in the goat, donkey and cat
was comparable to humans, which indicates it is likely to be an
effective analgesic at typically used doses in these species but not
in dogs or horses.
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